Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Opsomer, D. Ruppert (1999)
A Root-n Consistent Backfitting Estimator for Semiparametric Additive ModelingJournal of Computational and Graphical Statistics, 8
J. Wasson, T. Bubolz, G. Lu-Yao, E. Walker-Corkery, C. Hammond, M. Barry (2000)
Transurethral resection of the prostate among medicare beneficiaries: 1984 to 1997. For the Patient Outcomes Research Team for Prostatic Diseases.The Journal of urology, 164 4
N. Day, S. Walter (1984)
Simplified models of screening for chronic disease: estimation procedures from mass screening programmes.Biometrics, 40 1
Ruth Etzioni, D. Penson, J. Legler, Dante Tommaso, R. Boer, P. Gann, E. Feuer (2002)
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.Journal of the National Cancer Institute, 94 13
Ruth Etzioni, K. Berry, J. Legler, Pamela Shaw (2002)
Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998.Urology, 59 2
Yu Shen, M. Zelen (2001)
Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 15
J. Richie, W. Catalona, F. Ahmann, M. Hudson, P. Scardino, R. Flanigan, J. Dekernion, T. Ratliff, L. Kavoussi, Bruce Dalkin, W. Waters, M. Macfarlane, P. Southwick (1993)
Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination.Urology, 42 4
Gann (1995)
A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancerJournal of the American Medical Association, 273
P. Pinsky (2001)
Estimation and Prediction for Cancer Screening Models Using Deconvolution and SmoothingBiometrics, 57
Yu-Ray Shen, M. Zelen (1999)
Parametric estimation procedures for screening programmes: Stable and nonstable disease models for multimodality case findingBiometrika, 86
A. Mariotto, Ruth Etzioni, Martin Krapcho, E. Feuer (2007)
Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview SurveyCancer, 109
Hastie (1986)
Generalized additive modelsStatistical Science, 3
Van Keilegom Van Keilegom, Carroll Carroll (2007)
Backfitting versus profiling in general criterion functionsStatistica Sinica
G. Draisma, R. Boer, S. Otto, I. Cruijsen, R. Damhuis, F. Schröder, H. Koning (2003)
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.Journal of the National Cancer Institute, 95 12
Eric Feuer, L. Wun (1992)
How much of the recent rise in breast cancer incidence can be explained by increases in mammography utilization? A dynamic population model approach.American journal of epidemiology, 136 12
P. Pinsky, G. Andriole, B. Kramer, R. Hayes, P. Prorok, J. Gohagan (2005)
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.The Journal of urology, 173 3
P. Gann, C. Hennekens, M. Stampfer (1995)
A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer.JAMA, 273 4
Ruth Etzioni, R. Cha, E. Feuer, O. Davidov (1998)
Asymptomatic incidence and duration of prostate cancer.American journal of epidemiology, 148 8
Stephen Walter, Nicholas Day (1983)
Estimation of the duration of a pre-clinical disease state using screening data.American journal of epidemiology, 118 6
A. Tsodikov, Aniko Szabo, Jake Wegelin (2006)
A population model of prostate cancer incidenceStatistics in Medicine, 25
Deborah Smith, A. Bullock, W. Catalona, J. Herschman (1996)
Racial differences in a prostate cancer screening study.The Journal of urology, 156 4
T. Severini, J. Staniswalis (1994)
Quasi-Likelihood Estimation in Semiparametric ModelsJournal of the American Statistical Association, 89
R. Merrill, E. Feuer, J. Warren, N. Schussler, R. Stephenson (1999)
Role of transurethral resection of the prostate in population-based prostate cancer incidence rates.American journal of epidemiology, 150 8
M. Zelen, M. Feinleib (1969)
On the theory of screening for chronic diseasesBiometrika, 56
G. Andriole, D. Levin, E. Crawford, E. Gelmann, P. Pinsky, D. Chia, B. Kramer, D. Reding, T. Church, R. Grubb, G. Izmirlian, L. Ragard, J. Clapp, P. Prorok, J. Gohagan (2005)
Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.Journal of the National Cancer Institute, 97 6
P. Eilers, B. Marx (1996)
Flexible smoothing with B-splines and penaltiesStatistical Science, 11
M. Zelen (1968)
A hypothesis for the natural time history of breast cancer.Cancer research, 28 2
John Wasson, T. Bubolz, G. Lu-Yao, E. Walker-Corkery, C. Hammond, M. Barry (2000)
TRANSURETHRAL RESECTION OF THE PROSTATE AMONG MEDICARE BENEFICIARIES: 1984 TO 1997The Journal of Urology, 164
Summary The introduction of the prostate‐specific antigen (PSA) test has led to dramatic changes in the incidence of prostate cancer in the United States. In this article, we use information on the increase and subsequent decline in prostate cancer incidence following the adoption of PSA to estimate the lead time associated with PSA screening. The lead time is a key determinant of the likelihood of overdiagnosis, one of the main costs associated with the PSA test. Our approach conceptualizes observed incidence as the sum of the secular trend in incidence, which reflects incidence in the absence of PSA, and the excess incidence over and above the secular trend, which is a function of population screening patterns and the unknown lead time. We develop a likelihood model for the excess incidence given the secular trend and use it to estimate the mean lead time under specified distributional assumptions. We also develop a likelihood model for observed incidence and use it to simultaneously estimate the mean lead time together with a smooth secular trend. Variances and confidence intervals are estimated via a parametric bootstrap. Our results indicate an average lead time of approximately 4.59 years (95% confidence interval (3.24, 5.93)) for whites and 6.78 years (5.42, 8.20) for blacks with a corresponding secular trend estimate that is fairly flat after the introduction of PSA screening. These estimates correspond to overdiagnosis frequencies of approximately 22.7% and 34.4% for screen‐detected whites and blacks, respectively. Our results provide the first glimpse of a plausible secular trend in prostate cancer incidence and suggest that, in the absence of PSA screening, disease incidence would not have continued its historic increase, rather it would have leveled off in accordance with changes in prostate patterns of care unrelated to PSA.
Biometrics – Wiley
Published: Mar 1, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.